title: Long-term effects of treatment of pituitary adenomas.
abstract: Pituitary adenomas can be treated effectively in the vast majority of cases. After successful treatment for pituitary disease, many patients still report reduced quality of life in the presence of persistent morbidity and (slightly) increased mortality. At present, there is an increasing awareness that in many cases long-term remission of functioning or nonfunctioning adenomas does not equal cure. The causes are most probably multifactorial. Hypopituitarism, intrinsic imperfections of surgical or endocrine replacement therapy, but also persistent effects of treatment and of previous hormone excess on the central nervous system all affect long-term morbidity, general well-being, and mortality. This implies that treatment goals for patients with pituitary adenomas will shift from long-term cure to long-term care. Further research is therefore needed to get more insight into each of these factors of influence, such as the extent of reversibility of hormone excess syndromes on cardiovascular risk and behavior. The fact that coping strategies, despite long-term remission, are altered and illness perceptions are affected strongly suggests that long-term care should incorporate self-management interventions that might help to improve quality of life for patients.
authors.affiliation: Department of Endocrinology and Center for Endocrine Tumors, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: A.M.Pereira@lumc.nl.
authors.forename: Alberto M
authors.initials: AM
authors.lastname: Pereira
mesh_terms: D000236:Adenoma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D000818:Animals; D006801:Humans; D007018:Hypopituitarism / Q000175:diagnosis / Q000209:etiology / Q000401:mortality; D010911:Pituitary Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
keywords: Long-term effects; hormone replacement; hypothalamic dysfunction; morbidity; mortality; pituitary adenoma; quality of life